Abivax SA ABVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ABVX is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- €14.74
- Day Range
- €14.58–14.90
- 52-Week Range
- €7.89–19.70
- Bid/Ask
- €14.52 / €14.92
- Market Cap
- €932.44 Mil
- Volume/Avg
- 13,478 / 29,346
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 61
- Website
- https://www.abivax.com
Comparables
Valuation
|
Metric
|
ABVX
|
MRNA
|
HALO
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 40.19 | 15.81 |
Price/Book Value | 4.73 | 2.98 | 58.34 |
Price/Sales | — | 6.11 | 6.24 |
Price/Cash Flow | — | — | 12.11 |
Price/Earnings
ABVX
MRNA
HALO
Financial Strength
|
Metric
|
ABVX
|
MRNA
|
HALO
|
|---|---|---|---|
Quick Ratio | 4.00 | 3.21 | 5.07 |
Current Ratio | 4.08 | 3.42 | 6.64 |
Interest Coverage | −9.89 | −113.82 | 19.57 |
Quick Ratio
ABVX
MRNA
HALO
Profitability
|
Metric
|
ABVX
|
MRNA
|
HALO
|
|---|---|---|---|
Return on Assets (Normalized) | −70.24% | −20.12% | 16.03% |
Return on Equity (Normalized) | −142.04% | −26.85% | 199.98% |
Return on Invested Capital (Normalized) | −89.54% | −26.68% | 18.45% |
Return on Assets
ABVX
MRNA
HALO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Phxbdydx | Mcynv | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Dbphlfd | Bgjwbf | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Yrdhclqm | Fqtgkz | $97.8 Bil | |
MRNA
| Moderna Inc | Wkfbtfvr | Wkssf | $41.3 Bil | |
ARGX
| argenx SE ADR | Wpzctvr | Fclkr | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Prhzybqc | Lffr | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rjzbcdln | Ksplxvf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ksmbxkwyw | Pwybjxy | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wprljjrd | Xnhlvfb | $12.5 Bil | |
INCY
| Incyte Corp | Vkpzvxlz | Nxlkyr | $11.6 Bil |